Harbin Gloria Pharmaceuticals Co., Ltd

Shenzhen Stock Exchange 002437.SZ

Harbin Gloria Pharmaceuticals Co., Ltd Operating Income Margin for the year ending December 31, 2023: 6.67%

Harbin Gloria Pharmaceuticals Co., Ltd Operating Income Margin is 6.67% for the year ending December 31, 2023, a 285.73% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Harbin Gloria Pharmaceuticals Co., Ltd Operating Income Margin for the year ending December 31, 2022 was -3.59%, a -172.10% change year over year.
Harbin Gloria Pharmaceuticals Co., Ltd Operating Income Margin for the year ending December 31, 2021 was 4.98%, a -80.62% change year over year.
Harbin Gloria Pharmaceuticals Co., Ltd Operating Income Margin for the year ending December 31, 2020 was 25.68%, a 305.32% change year over year.
Harbin Gloria Pharmaceuticals Co., Ltd Operating Income Margin for the year ending December 31, 2019 was 6.34%, a 101.87% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

Shenzhen Stock Exchange: 002437.SZ

Harbin Gloria Pharmaceuticals Co., Ltd

CEO	Mr. Leifeng Guo
IPO Date	Oct. 27, 2011
Location	China
Headquarters	No. 29, Beijing Road
Employees	3,085
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Harbin Gloria Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products primarily in the People's Republic of China. It offers cardiac cerebrovascular medication, skeletal muscle system, vitamins and minerals, urinary system medication, antitumor medication, endocrine medicine, anti-infective drugs, respiratory medication, antihistamine, peptic, and other products. Harbin Gloria Pharmaceuticals Co., Ltd. was founded in 2000 and is based in Harbin, the People's Republic of China.

Key trends

Past 5 years